NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Fourth Quarter Financial Results

On March 14, 2018, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2017. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Items 2.02 and 9.01 of this Form 8-K (excluding Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 14, 2018, the Board of Directors of the Company appointed John J. Trizzino, age 58, as Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer of the Company. Prior to his appointment, Mr. Trizzino had served as Senior Vice President, Commercial Operations since he rejoined the Company in 2014. He previously served as the Company’s Senior Vice President, Business Development from August 2010 to September 2011, and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Prior to rejoining the Company, Mr. Trizzino was the Chief Executive Officer of Immunovaccine Inc. from September 2011 to September 2013.

The Company is currently compensating Mr. Trizzino in accordance with the terms of his employment agreement with the Company, dated February 26, 2014, which is filed as Exhibit10.3 to the Company’s Quarterly Report on Form10-Q filed with the Securities and Exchange Commission on May5, 2016.

A press release announcing Mr.Trizzino’s appointment is filed as Exhibit99.2 hereto.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

NOVAVAX INC Exhibit
EX-99.1 2 tv488645_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1       Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results   ·RSV Phase 3 Prepare™ Trial Outcome De-risked by Successful Informational Analysis ·NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based,…
To view the full exhibit click here

About NOVAVAX, INC. (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).